ddC (Zalcitabine)

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 257-269

  Skowron, Gail ^b  

^a BROWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; RIBAVIRIN; SAQUINAVIR; U 90153; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL COUNT; CONFERENCE PAPER; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT SELECTION; PRIORITY JOURNAL; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029933341     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_23     Document Type: Conference Paper

References (49)

1. H. Mitsuya, S. Broder. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci. USA. 83:1911-1915 (1986).
2. W-Y. Gao, T. Shirasaka, D.G. Johns, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 91:2326-2333 (1993).
3. W-Y. Gao, R. Agbaria, J.S. Driscoll, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 269:12633-12638 (1994).
4. C-F. Perno, R. Yarchoan, D.A. Cooney, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GMCSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′,3′-dideoxythymidine (AZT) and other dideoxynucleosides. J Exp Med. 169:933-951 (1989).
5. J.J. Eron, V.A. Johnson, D.P. Merrill, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agents Chemother. 36:1559-1562 (1992).
6. M.W. Vogt, A.G. Durno, T-C. Chou, et al. Synergistic interaction of 2′,3′-dideoxycytidine and recombinant interferon-α on replication of human immunodeficiency virus type 1. J Infect Dis. 158:378-385 (1988).
7. V.A. Johnson, D.P. Merrill, T-C. Chou, et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-α against zidovudine-sensitive or -resistant HIV-1 in vitro. J Inf Dis. 166:1143-1146 (1992).
8. K-T. Chong, P.J. Pagano, R.R. Hinshaw. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-Azido-3′-Deoxythymidine or 2′,3′-Dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 38:288-293 (1994).
9. M.W. Vogt, K.L. Hartshorn, P.A. Furman, et al. Ribavirin antagonizes the effects of azidothymidine on HIV replication. Science. 235:1376-1379 (1987).
10. M. Baba, R. Pauwels, J. Balzarini, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2′, 3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 31:1613-1617 (1987).
11. R. Yarchoan, C.R. Perno, R.V. Thomas, et al. Phase I studies of 2′, 3′ dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. I, 76-81 (1988).
12. T.C. Merigan, G. Skowron, S. Bozzette, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections. Annals Int Med. 110:189-94 (1989).
13. A.R. Berger, J.C. Arezzo, H.H. Schaumburg, et al. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 43:358-362 (1993).
14. T.C. Merigan, G. Skowron and the ddC Study Group of the AIDS Clinical Trials Group of the NIAID. Safety and tolerance of dideoxycytidine as a single agent. Amer J Med. 88(suppl 5B):11S-15S (1990).
15. M. Gottlieb, J. Galpin, J. Thompkins, et al. 2′,3′-dideoxycytidine (ddC) in the treatment of patients with AIDS and ARC (abstract). Fifth International Conference on AIDS, Montreal, Canada, June 4-9, 1989.
16. R. W. Klecker, J.M. Collins, R.C. Yarchoan, et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 28:837-842 (1988).
17. Hoffman La-Roche, letter to investigators, December 23, 1991.
18. M.A. Fischl, R.M. Olson, S.E. Follansbee, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Int Med. 118:762-769 (1993).
19. M. Fischl, K. Stanley, A. Collier, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 122:24-32 (1995).
20. Food and Drug Administration, Transcript of the Antiviral Drug Products Advisory Committee Meeting, September 20, 1993.
21. D.I. Abrams, A.I. Goldman, C. Launer, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med. 330:657-662 (1994).
22. S.A. Spector, S. Blanchard, E.M. Conner, et al. Results of a clinical trial comparing two doses of 2′,3′-dideoxycytidine (ddC) in the treatment of children with symptomatic human immunodeficiency virus (HIV) infection who were intolerant or had failed zidovudine (ZDV) therapy (ACTG 138). Am Ped Soc. Abstract 1165:197A (1994).
23. G. Skowron, S.A. Bozzette, L Lim, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Int Med 1993;118:321.
24. S. Bozzette, G. Skowron, J. Arezzo, et al. ACTG 050: Alternating (ALT) and (INT) ddC and AZT in the treatment of persons with advanced HIV infection and hematologic intolerance to AZT. Sixth International Conference on AIDS, San Francisco, CA, June 20-24, 1990, abstract S.B. 425.
25. P.A. Pizzo, K. Butler, F. Balis, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Ped. 117:799-808 (1990).
26. B-YT. Nguyen, L.E. Shay, K.M. Wyvill, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis 168:810-817 (1993).
27. M. Liu, J.L. Fahey, N. Aziz, et al. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. J Infect Dis. 170:1165-1171 (1994).
28. D.D. Richman, J.M. Grimes, S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immuno-deficiency virus. J AIDS. 3:743-746 (1990).
29. D.D. Richman, M.A. Fischl, M.H. Grieco, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS-related complex a double-blind, placebo-controlled trial. N Eng J Med. 317:192-197 (1987).
30. T-C Meng, M.A. Fischl, A.M. Boota, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Int Med. 116:13-20 (1992).
31. D.D. Richman, T-C. Meng, S.A. Spector, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J AIDS. 7:135-38 (1994).
32. R. Schooley, B. Larder, M. St. Clair, et al. Combination antiretroviral therapy in previously untreated individuals. Wellcome Foundation Symposium, Yokohama, Japan August 7, 1994.
33. R. Bassett, D. Schoenfeld, A.C. Collier for the ACTG 229 Protocol Team. ACTG 229 Executive Summary May 26, 1994. Division of AIDS, National Institute for Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD.
34. A.C. Collier, R.W. Coombs, J. Timpone, et al. Comparative study of Ro31-8959 and Zidovudine (ZDV) vs ZDV and Zalcitabine (ddC) vs. Ro 31-8959, ZDV, and ddC. 10th International Conference on AIDS, August 7-12, 1994, Yokohama, Japan. abstract 058B:21.
35. T. Shirasaka, R. Yarchoan, M.C. O'Brien, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci. 90:562-566 (1993).
36. J.E Fitzgibbon, R.M. Howell, C.A. Haberzettl, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-didcoxycytidine. Antimicrob Agents Chemother. 36:153-157 (1992).
37. J.E. Fitzgibbon, A.E. Farnham, S.J. Sperber, et al. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol. 67:7271-7275 (1993)
38. D.D. Richman, J.M. Grimes, and S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS. 3:743-746. (1990).
39. R. Schuurman, M. Nijhuis, R. van Leeuwen, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1411-1419. (1995).
40. Z. Gu, Q. Gao, X. Li, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxycytidine. J Virol. 66:7128-7135 (1992).
41. D. Zhang, A.M. Caliendo, J.J. Eron, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 38:282-287 (1994).
42. Z. Gu, Q. Gao, H. Fang, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 38:275-281 (1994).
43. B.A. Larder, S.D. Kemp, and P.R. Harrigan. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269:696-699. (1995).
44. T. Shirasaka, M.F. Kavlick, T. Ueno, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci. USA. 92:2398-2402. (1995).
45. M.H. St. Clair, J.L. Martin, G. Tudor-Williams, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1reverse transcriptase Science. 253:1557-1559 (1991).
46. R.W. Shafer, M.J. Kozal, M.A Winters, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type I strains with unique patterns of pol gene mutations. J Infect Dis. 169:722-729. (1994).
47. S.F. Lacey and B. A. Larder. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 38:1428-1432. (1994).
48. D. Mayers, A. Japour, J-M. Arduino, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 38:307-314 (1994).
49. M.A. Sande, C.C.J. Carpenter, G. Cobbs, et al. Antiretroviral therapy for adult HIV-infected patients: Recommendations from a State-of-the-Art Conference. JAMA 270:2583-2589 (1993).